Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
(1) Objective: To evaluate the efficacy of each treatment arm of GZR/EBR (MK-5172A) in combination with Sofosbuvir (SOF) +/- Ribavirin (RBV) as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy), defined as HCV RNA <LLOQ (either TD[u] or TND) 12 weeks after the end of all study therapy. (2) Objective:To evaluate the safety and tolerability of GZR/EBR (MK-5172A) in combination with SOF +/- RBV.
Critère d'inclusion
- Hepatitis C infection